Gastric Pacing/Gastric Electrical Stimulation - Medicare Advantage

This policy addresses gastric electrical stimulation (GES)/gastric pacing, including use of the FDA‑approved Enterra II system, as a treatment for chronic, intractable nausea and vomiting from diabetic or idiopathic gastroparesis in adults (typically 18–70 years) with symptoms refractory to diet modification and medical therapy and with diagnosis confirmed by gastric emptying testing. Major limitations: the provided excerpt contains no explicit coverage determination (coverage is governed by applicable CMS NCDs/LCDs/LCAs and MAC policies), describes a temporary trial of GES as investigational, notes gastric pacing devices are not FDA‑approved/clinically available in the US, and identifies device‑specific issues (revisions/removals, battery replacement every 5–10 years) as procedural considerations.

"Medication records or documentation confirming the individual is not concurrently treated with opioid medications"